caprotec bioanalytics Completes Series B Financing Round of EUR 4 Million
“CCMS is a broadly applicable technology to investigate small molecule protein interactions. It enables the isolation and identification of native functionally selected proteins directly from a complex biological sample,” stated Prof. Köster, founder and CEO of caprotec bioanalytics GmbH.
Karlheinz Schmelig, Managing Director at Creathor Venture commented, “The completion of this investment round in a challenging financing environment demonstrates that caprotec, with its exceptional management and ground breaking new technology, stands out among other companies in this industry.”
The proceeds from this financing round will be used to further develop caproKitsTM as tools for the worldwide R&D community to identify functionally selected protein classes and the company’s ImproMedTM (”improved medicines”) application to profile drug-protein interactions, generating the information to structurally optimize the drug molecule for increasing efficacy and reducing adverse side effects.
Most read news
Other news from the department business & finance
Get the analytics and lab tech industry in your inbox
From now on, don't miss a thing: Our newsletter for analytics and lab technology brings you up to date every Tuesday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.